Indira Chandran V, Eppenberger-Castori S, Venkatesh T, Vine K, Ranson M
Oncoscience. 2015; 2(3):207-24.
PMID: 25897424
PMC: 4394126.
DOI: 10.18632/oncoscience.146.
Gertler F, Condeelis J
Trends Cell Biol. 2010; 21(2):81-90.
PMID: 21071226
PMC: 3402095.
DOI: 10.1016/j.tcb.2010.10.001.
Wang W, Eddy R, Condeelis J
Nat Rev Cancer. 2007; 7(6):429-40.
PMID: 17522712
PMC: 4270061.
DOI: 10.1038/nrc2148.
Okada F, Kobayashi M, Tanaka H, Kobayashi T, Tazawa H, Iuchi Y
Am J Pathol. 2006; 169(1):294-302.
PMID: 16816381
PMC: 1698756.
DOI: 10.2353/ajpath.2006.060073.
N Tzanakakis G, Krambovitis E, Tsatsakis A, Vezeridis M
Int J Gastrointest Cancer. 2003; 32(1):23-30.
PMID: 12630766
DOI: 10.1385/IJGC:32:1:23.
Spontaneous but not experimental metastatic activities differentiate primary tumor-derived vs metastasis-derived mouse prostate cancer cell lines.
Hall S, Thompson T
Clin Exp Metastasis. 1997; 15(6):630-8.
PMID: 9344047
DOI: 10.1023/a:1018499515883.
Variable susceptibility to NK activity of cloned cell lines derived from a primary rat rhabdomyosarcoma: relationship to metastatic potential.
Poupon M, Judde J, Sweeney F, Lespinats G
Br J Cancer. 1983; 48(1):75-82.
PMID: 6871080
PMC: 2011409.
DOI: 10.1038/bjc.1983.159.
Experimental systems for analysis of the malignant phenotype.
Poste G
Cancer Metastasis Rev. 1982; 1(2):141-99.
PMID: 6764376
DOI: 10.1007/BF00048224.
The experimental and clinical implications of cellular heterogeneity in malignant tumors.
Poste G, Greig R
J Cancer Res Clin Oncol. 1983; 106(3):159-70.
PMID: 6654949
DOI: 10.1007/BF00402602.
Tumor heterogeneity: biological implications and therapeutic consequences.
Heppner G, Miller B
Cancer Metastasis Rev. 1983; 2(1):5-23.
PMID: 6616442
DOI: 10.1007/BF00046903.
The selective nature of metastasis.
Talmadge J
Cancer Metastasis Rev. 1983; 2(1):25-40.
PMID: 6616441
DOI: 10.1007/BF00046904.
Spontaneous metastasis: random or selective?.
Milas L, Peters L, Ito H
Clin Exp Metastasis. 1983; 1(4):309-15.
PMID: 6546204
DOI: 10.1007/BF00121193.
High-metastatic clones selected in vitro from a recent spontaneous BALB/c mammary adenocarcinoma cell line.
Lollini P, De Giovanni C, Eusebi V, Nicoletti G, Prodi G, Nanni P
Clin Exp Metastasis. 1984; 2(3):251-9.
PMID: 6543703
DOI: 10.1007/BF00132932.
Pattern of organ colonization of metastasizing mouse L929-MM4 cells and the stimulation of lung tumor formation by cyclophosphamide.
Gavilondo Cowley J, Fernandez Ordonez A, Amador Perez J
Clin Exp Metastasis. 1984; 2(3):241-50.
PMID: 6543702
DOI: 10.1007/BF00132931.
Inhibition of lymphocyte mitogenesis by factor(s) released from macrophages isolated from ascitic fluid of advanced ovarian cancer patients.
Sheid B, Boyce J
Cancer Immunol Immunother. 1984; 17(3):190-4.
PMID: 6332671
PMC: 11039279.
DOI: 10.1007/BF00205484.
Intratumor immunologic heterogeneity.
Miller F
Cancer Metastasis Rev. 1982; 1(4):319-34.
PMID: 6192904
DOI: 10.1007/BF00124215.
Implications of tumor progression on clinical oncology.
Welch D, Tomasovic S
Clin Exp Metastasis. 1985; 3(3):151-88.
PMID: 3902300
DOI: 10.1007/BF01786761.
Dynamic heterogeneity: isolation of murine tumor cell populations enriched for metastatic variants and quantification of the unstable expression of the phenotype.
Young S, Hill R
Clin Exp Metastasis. 1986; 4(3):153-76.
PMID: 3742890
DOI: 10.1007/BF00117930.
Metastatic instability of murine tumor metastases: dependence on tumor type.
Volpe J, Milas L
Clin Exp Metastasis. 1988; 6(4):333-46.
PMID: 3359715
DOI: 10.1007/BF01753580.
Perspectives in the treatment of cancer metastasis.
Garattini S
Clin Exp Metastasis. 1987; 5(2):105-24.
PMID: 3297448
DOI: 10.1007/BF00058057.
